Nilutamide

C₁₂H₁₀F₃N₃O₄

317.22

MFCD00864670

24278596

NA.77

Nilutamide has been used:

• as a nuclear androgen receptor (nAR) inhibitor to study its effects on oocyte maturation in zebrafish
• to determine its effects on bioluminescent Saccharomyces cerevisiae bioreporters in BLYAS assay
• as a substrate in hydrogenation reaction

Nilutamide is a nuclear androgen receptor inhibitor. It is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone to the androgen receptor. Nilutamide shows a therapeutic effect against prostate cancer.

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. N8534.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

200

solid

Sanofi Aventis

CC1(C)NC(=O)N(c2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)C1=O

1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)

XWXYUMMDTVBTOU-UHFFFAOYSA-N

human ... AR(367)

1 g in glass bottle

GHS06,GHS08

Danger

H301 - H360

P201 - P301 + P310 + P330

Acute Tox. 3 Oral - Repr. 1B

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK 3

Eyeshields, Faceshields, Gloves, type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges